A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Hoffmann-La Roche
Bristol-Myers Squibb
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Shanghai JMT-Bio Inc.
CSPC Megalith Biopharmaceutical Co.,Ltd.
RemeGen Co., Ltd.
Seattle Project Corporation
InnoPharmax Inc.
Tyme, Inc
Ono Pharmaceutical Co. Ltd
RemeGen Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Sorrento Therapeutics, Inc.
Hutchmed
Merrimack Pharmaceuticals